Bulletin of the Russian Military Medical AcademyBulletin of the Russian Military Medical Academy1682-73922687-1424Eco-Vector6356210.17816/brmma63562Research ArticleUltra-low dose estradiol plus dydrogesterone: a role in prevention of the development and progression of atherosclerosisKryukovEvgeniy V.<p>MD, PhD, Professor</p>evgeniy.md@mail.ruhttps://orcid.org/0000-0002-8531-0205PopovaLyudmila V.<p>Сandidate of medical sciences</p>mila_foka@mail.ruhttps://orcid.org/0000-0002-3496-6466VasilievSergey V.<p>Doctor of mathematical sciences, professor</p>vasilivsenator@gmail.comhttps://orcid.org/0000-0002-3485-4050PanevinTaras S.<p>Endocrinologist</p>tarasel@list.ruhttps://orcid.org/0000-0002-5290-156XPanevinaAnna S.<p>Сandidate of medical sciences</p>annapv3010@gmail.comhttps://orcid.org/0000-0003-2744-7550StromskayaUlyana Andreevnayavisya@list.ruhttps://orcid.org/0000-0002-4040-9658SamoilovaNatalia V.<p>Сandidate of medical sciences</p>nsamoylova2@yandex.ruMakarovOleg E.<p>Сandidate for a degree</p>Lioton@yandex.ruChief Military Clinical Hospital named after N.N. BurdenkoMilitary Medical Academy named after S.M. KirovAll-Russian Association for the Study of Thrombosis, Hemorrhagia and Vascular Pathology named after A.A. Schmidt and B.A. KudryashovThe First Moscow State Medical University named after I.M. Sechenov120520212319141703202117032021Copyright © 2021, Kryukov E.V., Popova L.V., Vasiliev S.V., Panevin T.S., Panevina A.S., Stromskaya U.A., Samoilova N.V., Makarov O.E.2021<p>Active development of the "anti-aging medicine", attempts to slow down biological (including vascular) aging led to the creation of new pharmaceuticals including menopausal hormone therapy. The vascular wall protective mechanism of the hormones is not completely clear, but it was shown that natural estrogens are able to control the condition of the vascular wall, prevent platelet adhesion, control a range of metabolic and trophic and energy processes in the endothelium of the vascular wall, producing antithrombogenic factors, namely their inhibition contributes to the development of atherosclerosis. It is known that standard and low-dose estrogen may restore the impaired antithrombogenic potential of the vascular wall, provided its initial reduction does not exceed 20%. The issue of the role and possibilities of correction of the antithrombogenic activity of the vascular wall with ultra-low dose estradiol remained unresolved. As a "clinical model" for the study of this issue, we formed 2 groups of patients: in the study group patients received ultra-low dose estradiol plus dydrogesterone, subjects from the control group received beta-alanine. Three-year follow-up showed a decrease in antithrombogenic activity of the vascular wall in control subjects after 2 and 3 years of follow-up according to the M.V. Baluda's test versus subjects treated with ultra-low dose estrogen plus dydrogesterone. The decrease of the relative risk of reduction of the antithrombogenic activity of the vascular wall with the use of ultra-low dose estrogen plus dydrogesterone during the first two years was 2.3 times, and during the 3 years of follow-up 3.8 times versus control. Thus, prescribing only ultra-low dose estradiol plus dydrogesterone for patients with normal antithrombogenic activity of the vessel wall at baseline reliably lowers the risk of long-term reduction of antithrombogenic potential of the vascular wall.</p>vascular agingmenopausal hormone therapyantithrombogenic activity of the vascular walldydrogesteronebeta-alaninatherosclerosisanti-aging medicineultra-low doseсосудистое старениеменопаузальная гормональная терапияантитромбогенная активность стенки сосудовдидрогестеронбета-аланинатеросклерозантивозрастная терапияультранизкодозированная[Potter B. Menopause. P. Care. 2018;4:625–641.][Kryukov EV, Panevin TS. Antitrombogenic vascular wall activity in women with climacteric myocardiodystrophy while menopause. Bulletin of Pirogov National Medical and Surgical Center. 2020;15(2):67–70. (In Russ.)][Tapilskaya NI, Glushakov RI. Principally, my friends, may brains not to get old. Potential of menopausal hormone therapy in brain aging prevention. StatusPraesens. Gynecology, obstetrics, infertility. 2019;(4):74–78. (In Russ.)][Chester RC, Kling DM, Manson DI. What the Women's Health Initiative has taught us about menopausal hormone therapy. Clin Cardiol. 2018;41(2):247–252. doi: https://doi.org/10.1002/clc.22891][Piróg M Jach R, Kacalska-Janssen O. Differential effect of the ultra-low dose and standard estrogen plus dydrogesterone therapy on thrombin generation and fibrinolysis in postmenopausal women. Acta Obstet Gynecol Scand. 2017;96(12):1438–1445.][Pinkerton JV, James AH. Management of Menopausal Symptoms for Women Who Are at High Risk of Thrombosis. Clin Obstet Gynecol. 2018;61(2):260–268. doi: https://doi.org/10.1097/GRF.0000000000000358][Godo S, Shimokawa H. Endothelial functions Arterioscler Thromb. Vasc Biol. 2017;(37):108–114.][Kryukov EV, Panevin TS, Popova LV. Aging of hemostasis. Clinical Medicine. 2020;98(1):9–12. (In Russ.)][Konukoglu D, Uzun H. Endothelial Dysfunction and Hypertension Adv Exp Med Biol. 2017;(956):511–540.][Baluda VP, Baluda MV, Deyanov II, et al. Physiology of hemostasis: study guide. Moscow, 1995. (In Russ.)][Panevina AS, et al. Alterations of proinflamatory cytokines and antitrombogenic vascular wall activity in case of menopausal hormone therapy use. Clinical medicine. 2018;96(11):1029–1033. (In Russ.)][Dinger J, Bardenheuer K, Heinemann K. Drospirenone plus estradiol and the risk of serious cardiovascular events in postmenopausal women. Climacteric. 2016;19(4):349–356.][Ivanova OY, Tugarinova MS, Maltseva NV, Timofeenko AI. Clinical case of pregnancy complicated by cardiomyopathy. StatusPraesens. Gynecology, obstetrics, infertility. 2020;(2/3)[65/67]:143–145. (In Russ.)][Maisch B, Volker R. Cardiomyopathies: classification, diagnosis, and treatment. Heart Fail Clin. 2012;8(1):53–78.][Yarmolinskaya MI, Makletsova SA, Ipastova ID. Comdined estrogen and gestogen contraceptives and thrombosis: view of actualist. StatusPraesens. Gynecology, obstetrics, infertility. 2017;38(2):69–78. (In Russ.)]